Stocks in play: Antibe Therapeutics Inc.
Announced Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial. Antibe Therapeutics Inc. shares T.ATE are trading unchanged at $0.47.
Read:
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments
Pioneering the Path to Cure Cancer: 2023's Biotech Innovations
Top Lithium Producer Predicts EVs Will Consume Almost All Lithium Supply by 2030
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges
The Future of Lithium: North America Poised to Break Dependence on Global Sources